Glucose Fresenius Kabi

Glucose Fresenius Kabi is an intravenous solution for injection that contains glucose monohydrate as the active ingredient. It is supplied in a sterile liquid form for parenteral administration and is marketed in the European Union. The product provides a readily available source of carbohydrate for patients who require rapid glucose supplementation or fluid replacement. It is administered by healthcare professionals under controlled conditions to ensure safety.

Glucose Fresenius Kabi is indicated for several clinical situations where rapid carbohydrate delivery or fluid balance is required.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to eat. - Fluid replacement in perioperative or emergency settings. - Provision of energy substrate during prolonged fasting or critical illness. - Dilution medium for certain intravenous drug preparations. - Support of metabolic needs during cardiac surgery or extracorporeal circulation.

Glucose Fresenius Kabi may be associated with adverse reactions typical of intravenous carbohydrate solutions; most are mild and self‑limiting, while others can be clinically significant and require monitoring.

Common: - Local irritation or pain at the injection site. - Transient hyperglycemia, especially in patients with impaired insulin response. - Mild electrolyte shifts, such as slight decreases in serum potassium. - Nausea or vomiting related to rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload causing pulmonary edema in susceptible individuals. - Allergic reactions, including rash, urticaria, or anaphylaxis. - Severe electrolyte imbalance such as hypernatremia or severe hypokalemia.

When using Glucose Fresenius Kabi, clinicians should assess patient-specific factors and monitor parameters to minimize risks associated with intravenous glucose therapy.

- Verify blood glucose levels before administration to avoid overt hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Use appropriate concentration and dilution to reduce risk of osmotic injury. - Monitor electrolytes, particularly potassium and sodium, during and after infusion. - Consider contraindications such as known hypersensitivity to glucose solutions. - Evaluate need for insulin therapy in diabetic patients receiving the product. - Ensure aseptic technique to prevent catheter‑related infections.

Glucose Fresenius Kabi can interact with other intravenous therapies or medications that affect glucose metabolism, fluid balance, or electrolyte status, requiring careful coordination.

Avoid: - Co‑administration with high‑concentration dextrose solutions without appropriate monitoring, which may cause severe hyperglycemia. - Simultaneous infusion of potassium chloride in undiluted form, increasing risk of hyperkalemia. - Mixing with acidic solutions can cause precipitation and loss of efficacy.

Use with caution: - Concurrent use of insulin or oral hypoglycemic agents; dose adjustments may be needed. - Administration alongside diuretics that alter fluid and electrolyte balance. - Use with calcium channel blockers in patients prone to fluid overload.